Key facts
- This page summarizes Robert Casale's Form 4 filing for PLx Pharma Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2022, 19:12.
Robert Casale - 22 Feb 2022 Form 4 Insider Report for PLx Pharma Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 22 Feb 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Natasha Giordano, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Robert Casale filed Form 4 for PLx Pharma Inc. on 24 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLXPQ
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 22 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $4.99
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended.
Footnote F2
These stock options vest in full on the first anniversary of the grant date.